Fosfomycin tromethamine

Drug Profile

Fosfomycin tromethamine

Alternative Names: Fosfomycin trometamol; FZ 588; Monofoscin; Monuril; Monurol; Urizone; Z 1282

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zambon Group SpA
  • Developer Adcock Ingram Pharmaceuticals; Allergan; Inpharzam Ricerche S.A.; Mayne Pharma Group; Orion; Rontag; Roux Ocefa; Zambon Company SpA
  • Class Antibacterials; Epoxy compounds; Organophosphorus compounds; Phosphonic acids; Phosphoric acid esters; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Urinary tract infections

Most Recent Events

  • 25 Sep 2017 Launched for Urinary tract infections in Turkey, Mexico, Indonesia, Taiwan, Philippines, Malaysia, Lebanon, Hong Kong, China, Thailand, Israel, Peru, Tunisia, Slovenia, Russia (PO)
  • 15 Sep 2017 Fosfomycin tromethamine licensed to Mayne Pharma Group in Australia
  • 04 Sep 2017 Registered for Urinary tract infections (In adolescents, In adults) in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top